vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Ouster, Inc. (OUST). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $62.2M, roughly 1.2× Ouster, Inc.). On growth, Ouster, Inc. posted the faster year-over-year revenue change (106.6% vs -36.9%). MEDIFAST INC produced more free cash flow last quarter ($-6.6M vs $-37.2M). Over the past eight quarters, Ouster, Inc.'s revenue compounded faster (54.8% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.

MED vs OUST — Head-to-Head

Bigger by revenue
MED
MED
1.2× larger
MED
$75.1M
$62.2M
OUST
Growing faster (revenue YoY)
OUST
OUST
+143.5% gap
OUST
106.6%
-36.9%
MED
More free cash flow
MED
MED
$30.5M more FCF
MED
$-6.6M
$-37.2M
OUST
Faster 2-yr revenue CAGR
OUST
OUST
Annualised
OUST
54.8%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
OUST
OUST
Revenue
$75.1M
$62.2M
Net Profit
Gross Margin
69.4%
60.2%
Operating Margin
-10.4%
1.5%
Net Margin
Revenue YoY
-36.9%
106.6%
Net Profit YoY
EPS (diluted)
$-1.64
$0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
OUST
OUST
Q4 25
$75.1M
$62.2M
Q3 25
$89.4M
$39.5M
Q2 25
$105.6M
$35.0M
Q1 25
$115.7M
$32.6M
Q4 24
$119.0M
$30.1M
Q3 24
$140.2M
$28.1M
Q2 24
$168.6M
$27.0M
Q1 24
$174.7M
$25.9M
Net Profit
MED
MED
OUST
OUST
Q4 25
Q3 25
$-2.3M
$-21.7M
Q2 25
$2.5M
$-20.6M
Q1 25
$-772.0K
$-22.0M
Q4 24
Q3 24
$1.1M
$-25.6M
Q2 24
$-8.2M
$-23.9M
Q1 24
$8.3M
$-23.8M
Gross Margin
MED
MED
OUST
OUST
Q4 25
69.4%
60.2%
Q3 25
69.5%
42.1%
Q2 25
72.6%
45.2%
Q1 25
72.8%
41.3%
Q4 24
74.1%
43.8%
Q3 24
75.4%
38.3%
Q2 24
73.2%
33.7%
Q1 24
72.8%
28.6%
Operating Margin
MED
MED
OUST
OUST
Q4 25
-10.4%
1.5%
Q3 25
-4.6%
-61.4%
Q2 25
-1.0%
-76.5%
Q1 25
-1.1%
-73.0%
Q4 24
0.6%
-85.1%
Q3 24
1.5%
-98.0%
Q2 24
-4.7%
-93.6%
Q1 24
4.5%
-99.5%
Net Margin
MED
MED
OUST
OUST
Q4 25
Q3 25
-2.5%
-55.0%
Q2 25
2.3%
-58.8%
Q1 25
-0.7%
-67.5%
Q4 24
Q3 24
0.8%
-91.1%
Q2 24
-4.8%
-88.4%
Q1 24
4.8%
-91.9%
EPS (diluted)
MED
MED
OUST
OUST
Q4 25
$-1.64
$0.10
Q3 25
$-0.21
$-0.37
Q2 25
$0.22
$-0.38
Q1 25
$-0.07
$-0.42
Q4 24
$0.08
$-0.46
Q3 24
$0.10
$-0.54
Q2 24
$-0.75
$-0.53
Q1 24
$0.76
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
OUST
OUST
Cash + ST InvestmentsLiquidity on hand
$167.3M
$208.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$261.7M
Total Assets
$248.0M
$349.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
OUST
OUST
Q4 25
$167.3M
$208.6M
Q3 25
$173.5M
$244.5M
Q2 25
$162.7M
$226.5M
Q1 25
$164.6M
$168.2M
Q4 24
$162.3M
$172.0M
Q3 24
$170.0M
$151.4M
Q2 24
$163.5M
$184.2M
Q1 24
$156.4M
$187.8M
Stockholders' Equity
MED
MED
OUST
OUST
Q4 25
$198.9M
$261.7M
Q3 25
$214.7M
$247.4M
Q2 25
$216.0M
$221.0M
Q1 25
$211.0M
$167.9M
Q4 24
$210.1M
$180.9M
Q3 24
$207.3M
$171.7M
Q2 24
$205.3M
$170.6M
Q1 24
$211.0M
$167.2M
Total Assets
MED
MED
OUST
OUST
Q4 25
$248.0M
$349.5M
Q3 25
$268.2M
$353.8M
Q2 25
$269.3M
$321.8M
Q1 25
$280.0M
$268.6M
Q4 24
$284.2M
$276.1M
Q3 24
$291.2M
$255.2M
Q2 24
$293.5M
$309.9M
Q1 24
$302.8M
$317.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
OUST
OUST
Operating Cash FlowLast quarter
$-5.3M
$-15.4M
Free Cash FlowOCF − Capex
$-6.6M
$-37.2M
FCF MarginFCF / Revenue
-8.8%
-59.8%
Capex IntensityCapex / Revenue
1.8%
35.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$-64.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
OUST
OUST
Q4 25
$-5.3M
$-15.4M
Q3 25
$12.1M
$-18.3M
Q2 25
$-3.4M
$-1.3M
Q1 25
$3.4M
$-4.9M
Q4 24
$-4.9M
$-2.6M
Q3 24
$9.1M
$-3.8M
Q2 24
$13.1M
$-21.6M
Q1 24
$7.3M
$-5.7M
Free Cash Flow
MED
MED
OUST
OUST
Q4 25
$-6.6M
$-37.2M
Q3 25
$10.8M
$-20.0M
Q2 25
$-4.8M
$-2.2M
Q1 25
$1.9M
$-5.4M
Q4 24
$-7.2M
$-4.0M
Q3 24
$7.7M
$-4.3M
Q2 24
$11.1M
$-22.0M
Q1 24
$5.4M
$-7.1M
FCF Margin
MED
MED
OUST
OUST
Q4 25
-8.8%
-59.8%
Q3 25
12.0%
-50.7%
Q2 25
-4.5%
-6.3%
Q1 25
1.6%
-16.6%
Q4 24
-6.1%
-13.3%
Q3 24
5.5%
-15.4%
Q2 24
6.6%
-81.5%
Q1 24
3.1%
-27.4%
Capex Intensity
MED
MED
OUST
OUST
Q4 25
1.8%
35.0%
Q3 25
1.5%
4.3%
Q2 25
1.3%
2.5%
Q1 25
1.3%
1.7%
Q4 24
1.9%
4.8%
Q3 24
1.0%
2.0%
Q2 24
1.1%
1.3%
Q1 24
1.1%
5.3%
Cash Conversion
MED
MED
OUST
OUST
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons